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Abstract
Background: Whole Exome Sequencing (WES) is one of the most used and cost-effective next generation
technologies that allows sequencing of all nuclear exons. Off-target regions may be captured if they present
high sequence similarity with baits. Bioinformatics tools have been optimized to retrieve a large amount of
WES off-target mitochondrial DNA (mtDNA), by exploiting the aspecificity of probes, partially overlapping to
Nuclear mitochondrial Sequences (NumtS). The 1000 Genomes project represents one of the widest resources
to extract mtDNA sequences from WES data, considering the large effort the scientific community is
undertaking to reconstruct human population history using mtDNA as marker, and the involvement of mtDNA
in pathology.
Results: A previously published pipeline aimed at assembling mitochondrial genomes from off-target WES reads
and further improved to detect insertions and deletions (indels) and heteroplasmy in a dataset of 1242 samples
from the 1000 Genomes project, enabled to obtain a nearly complete mitochondrial genome from 943 samples
(76% analyzed exomes). The robustness of our computational strategy was highlighted by the reduction of reads
amount recognized as mitochondrial in the original annotation produced by the Consortium, due to NumtS
filtering.
An accurate survey was carried out on 1242 individuals. 215 indels, mostly heteroplasmic, and 3407 single base
variants were mapped. A homogeneous mismatches distribution was observed along the whole mitochondrial
genome, while a lower frequency of indels was found within protein-coding regions, where frameshift mutations
may be deleterious. The majority of indels and mismatches found were not previously annotated in mitochondrial
databases since conventional sequencing methods were limited to homoplasmy or quasi-homoplasmy detection.
Intriguingly, upon filtering out non haplogroup-defining variants, we detected a widespread population occurrence
of rare events predicted to be damaging. Eventually, samples were stratified into blood- and lymphoblastoid-
derived to detect possibly different trends of mutability in the two datasets, an analysis which did not yield
significant discordances.
Conclusions: To the best of our knowledge, this is likely the most extended population-scale mitochondrial
genotyping in humans enriched with the estimation of heteroplasmies.
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Background
Mitochondrial DNA (mtDNA) polyploidy is a physiologic
trait of human cells and implicates the possibility of the
co-existence of different mtDNA genotypes within the
same cell, tissue, or individual, a condition known as het-
eroplasmy. Up to date, quantification of heteroplasmy
remains a challenging task in the characterization of
mitochondrial variants and a limit for conventional
sequencing methods [1]. The advent of Next Generation
Sequencing (NGS) technologies has revolutionized the
field of genomics, providing the possibility of unprece-
dented large-scale and high-throughput analyses. Indeed,
massive-parallel sequencing implies ultra-deep yields,
allowing the quantification of mitochondrial heteroplas-
mic variants [2,3]. One of the recent applications of NGS
is Whole Exome Sequencing (WES), a powerful and
quite cost-effective strategy to perform targeted deep
sequencing of genomic protein coding regions [4]. Even
though the most recent WES protocols include the use of
specific baits targeted to mtDNA, the majority of kits
currently used is devoted to the enrichment of nuclear-
coding DNA, while mtDNA targeting has mostly been
neglected [5]. Nonetheless, it was recently demonstrated
that the precious information of mitochondrial genotype
may be retrieved from off-target DNA in human WES
studies, even when designed for nuclear DNA exclusively
[6]. It was indeed observed that the overlapping of
nuclear probes onto nuclear mitochondrial sequences
(NumtS [7]) determines a cross-hybridization of such
baits with mtDNA, which in turn is brought along as a
‘contaminant’ [6]. The natural abundance of the mito-
chondrial molecules in cells allows to achieve a high read
depth, so that a recovery and assembly of the mtDNA
genome from nuclear WES studies is indeed feasible [6]
together with the quantification of heteroplasmy wher-
ever the mitochondrial genome is sufficiently covered.
The relevance of estimating mitochondrial hetero-
plasmy is further highlighted by the fact that mtDNA
mutations exert their phenotypic effect above a certain
mutation load threshold [8,9], which may vary depending
on the type of change [8,10] and tissue. Indeed, several
studies demonstrated that mtDNA mutations are func-
tionally recessive until the mutant load exceeds a specific
threshold and leads to a biochemical dysfunction [8,9,11].
In fact mitochondrial mutations are largely involved in
various diseases, aging and cancer [12]. In addition, the
finest quantification of heteroplasmy among familiar
lineages is helpful for forensic studies [13] and to better
understand mechanisms of intergenerational segregation,
especially in the case of maternal transmission of muta-
tions predisposing to mtDNA disorders [14].
Even though since 1995 it is known that heteroplasmy
in normal individuals may not be a rare biological status
[15], only recent surveys on mitochondrial genotyping
and heteroplasmy annotation with deep sequencing have
revealed that in normal human cells a widespread hetero-
geneity of mtDNA variants co-existence occurs in healthy
subjects and varies among tissues [1]. Moreover, a condi-
tion of ‘universal heteroplasmy’ was depicted by Chinnery
and colleagues in their recent work [16] in which they
observed, by using high-throughput technologies, the
presence of very low-level heteroplasmic variants in
related and unrelated individuals, likely due to inherited
or somatic events, not predicted to be pathogenic.
So far, consistently with the limited sensitivity of stra-
tegies and with the restricted population sampling avail-
able for mitochondrial genotyping, commonly used
mitochondrial portals and databases [17,18] do not
report heteroplasmy values for the mutations/variants
whose fraction has been reported in literature. However,
while such information is lacking in databases, nucleo-
tide and amino acid sites variability is at least available
within HmtDB [18] as a valuable information that con-
tributes both to the definition of haplogroups and to the
recognition of private variants or mutations with a
potential pathogenic role.
In this work we used a pipeline previously provided [6],
that we further implemented for insertions and deletions
(indels) calling and applied to the in silico extraction and
characterization of mitochondrial DNA from nuclear
WES studies, comprising 1242 exome samples of the
1000 Genomes project [19] belonging to 19 different
human populations. 1000 Genomes Project WES studies
represent one of the widest nuclear genomic resources
available to the scientific community, yet strikingly, up to
now, mtDNA genotyping has been disregarded, despite
the important contribution the small mitochondrial gen-
ome provides to the cell homeostasis. We were able to
recover mtDNA from all WES studies and to assemble
the complete mitochondrial genome for the majority of
analyzed samples. High quality metrics were used to filter
mismatches and indels and related heteroplasmy values
of filtered variants were recorded. We enriched these
data with a functional characterization, firstly detecting
haplogroup and non-haplogroup defining sites. Variabil-
ity estimation reported in the human mitochondrial data-
base and predictions of pathogenicity [20-22] were also
applied to non-haplogroup defining variants, revealing an
intriguingly heterogeneous scenario among populations.
We also performed a comparison between lymphoblas-
toid cell lines (LCLs) and blood-derived mitochondrial
DNA isolated from the group of available samples, in
order to assess the possible presence of genotype differ-
ences among the two different DNA sources, as pre-
viously tested for nuclear DNA [23-25]. Finally, in line
with the recent finding of the widespread distribution of
heteroplasmy among healthy individuals, we found a con-
sistent enrichment, among all 19 human populations
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screened, of very low-levels heteroplasmies, mostly
unshared between subjects and associated with very low
variability values reported in HmtDB, which more likely




We surveyed Whole Exome Sequencing (WES) datasets
related to 1242 individuals, available through the 1000
Genomes project site [26]. These individuals included
827 samples of the 1000 Genomes Phase 1 data collec-
tion, while the remaining 415 were additional indivi-
duals (Additional File 1), listed within the 2012-05-22
exome alignment index [27], which comprised all the
exome samples aligned by the Consortium until then.
Our dataset included 625 females and 617 males, from
19 different populations in total (Table 1). The set of
samples was selected considering different criteria:
sequences were all Illumina paired-end reads whose
mates were both mapped onto the references (Genome
Reference Consortium Human Reference 37, GRCh37/
hg19 [GenBank:GCA_000001405.1] for nuclear reads,
and the revised Cambridge Reference Sequence, rCRS
[GenBank:J01415.2] for mitochondrial reads), using the
Burrows-Wheeler Aligner (BWA) [28]. Two different
platforms for whole exome capture were used for the
samples analyzed: SeqCap EZ Human Exome Library
v1.0 and v2.0 from NimbleGen (for 515 samples) and
SureSelect All Exon V2 Target Enrichment from Agilent
(for 723 samples) [19], whereas for four samples it was
not possible to retrieve any information. All the infor-
mation about our 1242 samples was available through
the 1000 Genomes web site [26].
Mitochondrial sequences recovery from 1000 Genomes
WES studies, variant calling and heteroplasmy assessment
We adopted a pipeline previously published [6] in order
to recover mtDNA from off-target sequences of WES
studies, removing reads similar to NumtS (Nuclear
Mitochondrial Sequences) [7] and maintaining only
reads with a univocal mapping onto the mitochondrial
genome. Original mitochondrial BAM (Binary SAM,
Sequence Alignment/Map format) files from the 1000
Genomes Project were first converted in fastq files using
the SamToFastq module of the Picard suite of tools
(v.1.68) [29] to apply the abovementioned pipeline,
which requires the usage of SAMtools (v.0.1.19) [30],
GSNAP (version 2012-01-11) [31] and python 2.7.1 [32].
After read mapping on the mitochondrial genome, using







Mitochondrial Mean Per Base
Depth
ACB African Caribbean in Barbados 58 47.34 48.15
ASW African Ancestry in Southwest USA 51 99.89 373.39
CDX Chinese Dai in Xishuangbanna, China 78 97.64 47.44
CEU Utah residents with ancestry from northern and
western Europe
67 96.87 311.71
CHB Han Chinese in Beijing, China 73 99.05 142.86
CHS Han Chinese South, China 90 88.16 40.87
CLM Colombian in Medellin, Colombia 48 93.14 234.13
FIN Finnish in Finland 81 85.35 96.45
GBR British From England and Scotland, UK 69 96.12 269.39
GIH Gujarati Indians in Houston, Texas, USA 77 47.3 41.54
IBS Iberian populations in Spain 58 83.67 106.6
JPT Japanese in Tokyo, Japan 74 94.02 217.41
KHV Kinh in Ho Chi Minh City, Vietnam 75 68.05 25.12
LWK Luhya in Webuye, Kenya 25 93.71 256.66
MXL Mexican Ancestry in Los Angeles, California, USA 58 99.91 409.61
PEL Peruvian in Lima, Peru 47 63.61 33.67
PUR Puerto Rican in Puerto Rico 70 82.13 87.29
TSI Toscani in Italia 62 98.36 328.96
YRI Yoruba in Ibadan, Nigeria 81 94.92 214.86
For each population the number of samples we considered and the mean coverage and depth of mitochondrial genomes we extracted from exome data, are
reported. Coverage and depth were estimated as average of scores in each sample belonging to the same population. Mean coverage of assembled
mitochondrial genomes ranges from 99.91 (Mexican Ancestry in Los Angeles, California, USA) to 47.30 (Gujarati Indians in Houston, Texas, USA). Mexicans show
also the highest mean per base depth (409.61), while the minimum depth score is for Kinh (Ho Chi Minh City, Vietnam) mitochondrial genomes (25.12).
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rCRS as reference sequence, the MarkDuplicates module
of the Picard tools was applied on obtained SAM files in
order to remove PCR duplicates. Duplicates filtering was
just recommended in the adopted pipeline, but we con-
sidered this step crucial for a correct allelic quantifica-
tion in our analysis. We extended variant call analysis
also to indels, since they were not completely taken into
account by the pipeline we used. In particular, we
observed that it was targeted only for the detection of
homoplasmic deletions, disregarding heteroplasmic
indels. Moreover, the tool previously developed did not
automatically quantify heteroplasmic fractions (HF) that
we instead implemented in our system. We thus imple-
mented a workflow in python programming language to
parse the SAM file CIGAR string [30] associated to each
pairwise aligned read, holding information on indel
events. Mismatches were instead analyzed directly from
the mtDNAassembly-table.txt output of the adopted
pipeline. Filtering of insertion events was performed
using quality score (QS≥25) and read depth (rd≥5) cut-
off values per position previously adopted [6], whereas
the goodness of a deletion event was evaluated on the
basis of its 5bp-long upstream and downstream flanking
region. Indeed, a median QS≥25 and rd≥5 were required
for the flanking regions to consider such deletion in the
genome assembly. HF was assessed as the fraction of
the variant read depth onto the total mitochondrial read
depth of the same position (for mismatches and dele-
tions) or of the 5’ flanking position (for insertions).
The adopted pipeline allowed also to produce a consen-
sus mitochondrial sequence for each individual, including
only mismatches equal or above a HF threshold of 0.75,
otherwise the corresponding IUPAC character for single
nucleotide variants was reported [6]. This consensus was
used for the haplogroup assignment and for the subse-
quent analysis of pathogenicity linked to non-synonymous
mismatches considering also all those variants under the
fixed threshold annotated with IUPAC code.
All mitochondrial unique variants detected in this
study are reported in a BED (Browser Extensible Data)
table (Additional file 2), generated from a VCF file
which is the output of the python script we developed
for the detection of indels and heteroplasmic fraction of
mitochondrial variants. The python script and the VCF
file (reporting all the detected mitochondrial variants
integrated with the related heteroplasmic fractions) are
available upon request.
Haplogroup assignment
Haplogroup assignment of 943 mitochondrial consensus
sequences was performed using the stand-alone mt-clas-
sifier tool, implemented in HmtDB [33], which uses the
Reconstructed Sapiens Reference Sequence (RSRS) [34]
as mitochondrial reference.
The samples were chosen among the best assembled
mitochondrial genomes within our dataset, harboring less
than 500 gaps in their sequence. The mt-classifier version
used refers to the Phylotree [35] mtDNA tree build 15.
Mitochondrial reference databases
Variants identified within the analyzed dataset were
compared with those already annotated within HmtDB
[18] and Mitomap [17].
Site variability values calculated on mitochondrial
nucleotide multi-aligned sequences from nearly 10,000
healthy individuals, were downloaded from HmtDB web
site [33]. Variability scores contributed to the recognition
of private variants or mutations with a potential patho-
genic role: they ranged from 0 to 1, where low variability
values may be suggestive of a novel haplogroup-defining
variant or a rare disease-linked mutation, while high varia-
bility scores were owned by common alleles within gen-
omes stored in HmtDB.
Mitochondrial coding and control regions point muta-
tions with reports of disease-associations were available
in Mitomap [36].
Pathogenicity predictions
Pathogenicity predictions on variants identified within the
analyzed dataset were estimated using MutPred [20],
Polyphen-2 [21] and SNPs&GO [22] online software, pro-
ducing 6 different scores and related prediction classes for
each variant. Pathogenicity values, ranging from 0 to 1,
allowed discriminating between potentially pathogenic and
neutral mutations. Each of the abovementioned software
presents a specific threshold of pathogenicity. We consid-
ered 0.70 as threshold for high pathogenicity score by
MutPred as suggested by Pereira et al. [37] and “disease”
prediction class by the other ones.
Hierarchical clustering analysis
A hierarchical clustering based on Euclidean distance
estimation was performed to evidence shared classes of
heteroplasmy within individuals with the aim to identify
a possible clusterization of samples belonging to the
same population sharing a similar number of variants
referred to the same heteroplasmic range. The heatmap
representation was used to visualize hierarchical cluster-
ing by rows and columns, using a matrix of numbers of
variants belonging to 11 different classes of hetero-
plasmy, as raw input data. The maPalette function from
the marray R package version 3.0.1 was used to define
heatmap colors, while the heatmap R function was used
to draw the heatmap.
Lymphoblastoid cell lines and blood subsets
We identified 60 potential blood samples among our
943 best assembled mitochondrial genomes and chose
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60 potential LCL samples on the basis of Epstein-Barr
virus (EBV) coverage values provided by the Consortium
[38]. Indeed an EBV coverage equal to 0 might indicate
blood derived DNA, while LCL samples were selected
among those with the highest EBV coverage (in this
case, higher than 400).
Statistical analyses
Spectra of variants (insertions, deletions, mismatches)
within blood and LCL samples were compared with
one-tailed and two-tailed Student t-tests. Fisher’s test
was applied to the distributions of blood and LCL het-
eroplasmic variants within mitochondrial loci and also
to the distributions of variants within the same datasets
per class of heteroplasmic fractions.
Results
Coverage and quality of assembled mitochondrial
genomes
We downloaded aligned exome data (as BAM files) related
to 1242 individuals of the 1000 Genomes Project from the
public repository [39]. Sequence reads were extracted
from the BAM files and re-aligned to the human reference
genomes to assemble mitochondrial genomes for all the
samples by applying Picardi’s pipeline [6].
The first step of our analysis was the assessment of
quality and coverage of the reconstructed mitochondrial
genomes. We found that 76% of them showed a nearly
complete assembly (mitochondrial genome coverage
>97%). The robustness of the computational strategy we
used was highlighted by the reduction of the read count
(an average of 30% per sample) mapped to the reference
mitochondrial genome with respect to the original anno-
tation by the 1000 Genomes Consortium. Two different
factors contributed to the reduction of the original num-
ber of reads, namely PCR duplicates removal and, parti-
cularly, NumtS filtering [7], disregarded in the mapping
step performed by the Consortium.
The mitochondrial assembly showed different mean
coverage values within the 19 analyzed populations
(Table 1): they ranged from 99.91% to 47.30% with
respect to the entire mitochondrial genome. Mean per
base depth was also widely variable, ranging from
409.61 to 25.12. Detailed data about mitochondrial gen-
ome coverage of each sample are reported in Additional
File 1.
Coverage and quality score (QS) statistics were per-
formed for each mitochondrial locus by estimating med-
ian read depth and QS (Additional File 3 and Additional
File 4). As already reported [6], a better efficiency in
mitochondrial reads extraction was obtained with the
Agilent enrichment kit, as suggested by comparing the
highest mitochondrial depth values obtained within the
same locus (MT-ND6) through the Agilent (274.57X)
and the NimbleGen samples (55.67X). Furthermore,
Agilent mitochondrial reads showed slightly higher
mean QS than NimbleGen (34.62 vs 32.22), with the
maximum and the minimum QS observed within the
same loci, MT-TS2 (35.82 vs 33.13) and MT-TR (34.30
vs 31.47) respectively. Intergenic regions within Agilent
and Nimblegen samples presented the same trend of QS
and coverage values as of D-Loop and coding regions
(data not shown).
To verify the robustness of our protocol, we further
selected a subset of 28 samples with a mitochondrial
genome coverage >99%, which were previously analyzed
with both low coverage Whole Genome Sequencing
(WGS) [40] and Exome Sequencing projects by the
Consortium [19]. The dataset included 2 samples for
14/19 populations. None of the analyzed exome samples
was found within the low coverage dataset for the
remaining 5 populations. We considered the subset of
28 samples (indicated as “Low Coverage Control” in
Additional File 1) with the aim of identifying possible
disagreements about variants detected by the Consor-
tium and our pipeline. We were able to detect up to
93.53% of mitochondrial variants per sample reported
within the low coverage Variant Call Format (VCF) file
generated by the Consortium (Additional File 5), while
45/89 were missed with exome samples as they were
not sufficiently covered. Moreover, on average 3 variants
per sample were not identified within exome samples,
although their positions were sufficiently covered,
whereas we were able to find more than 10 variants per
sample not previously annotated with low coverage ana-
lysis by the Consortium. The latter were all heteroplas-
mic and about the 70% presented a HF<0.10, proving
the sensitivity of our pipeline.
Haplogroup assignment of reconstructed mitochondrial
genomes
The haplogroup assignment procedure helped to test the
quality of reconstructed mitochondrial sequences, since
the geographical areas of sampled individuals were
known. To this aim, we selected 943 out of 1242 sam-
ples (Methods section), which were analyzed by applying
the mt-classifier implemented in HmtDB [18]. Generally
the predicted haplogroups seemed to converge with
individual ethnicity.
About 93% of the 943 reconstructed sequences pre-
sented a prediction reliability P_Hg >90%, defined as the
highest fraction of Nph (recognized SNPs in the sequence
which define haplogroup (Hg) according to Phylotree (ph)
classification [35]) over the total number of the hap-
logroup-defining expected sites (Nph_exp) [18]. This high
percentage of true-positive haplogroup-defining variant
sites confirmed the high sensitivity of our method.
Assigned haplogroups are reported in Additional file 1.
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Indels and mismatches recognition, mapping and in silico
validation
An accurate analysis of indels and mismatches was carried
out on our mitochondrial dataset, considering the role
played by these mutation events in healthy and pathologi-
cal samples [41,42]. In considering the values reported
below it is important to take into account that the same
event may be observed in diverse samples in a different
heteroplasmic status. Two hundred and fifteen unique
mtDNA indel events (149 deletions and 66 insertions),
mostly heteroplasmic, were firstly recognized within the
1242 mitochondrial genomes analyzed (Additional File 6),
mapped onto the mitochondrial genome (Figure 1) and
then compared with indels already annotated in mitochon-
drial databases [17,18] (Additional File 6).
About 56% samples harbored at least one deletion and
64% presented an insertion (Additional File 7). The most
common events were single-base insertions (in 69% cases)
and deletions involving up to 3 bases (in 50% cases; data
not shown). However their distribution normalized to the
length of each mitochondrial locus showed high peaks of
indels ratio within the D-loop, while a lower number was
present within coding regions, where frameshift mutations
may be deleterious (Figure 1).
Interestingly, a certain amount of deletions was
detected also within genes for transfer RNA. Intergenic
regions, not shown in Figure 1, included 6 heteroplasmic
insertions, 3 heteroplasmic deletions and 2 homoplasmic
deletions.
The majority of the indels identified (72.09%) occurred
within homopolymeric stretches (Additional file 8),
defined as regions with the same nucleotide in at least
two adjacent positions. The shortest homopolymers har-
bored the highest number of indels, although 5-bases
stretches presented high levels of both deletions and
insertions too, with the exception of G-stretches. This
result was quite expected considering the homopolymeric
nucleotide compositional bias of the mitochondrial gen-
ome, and that almost all of the homopolymers (70%)
within the mitochondrial reference genomes (rCRS and
RSRS) are represented by two-bases stretches. Moreover,
up to 25% of the identified indels mapped within mito-
chondrial tandem repeat regions, where the onset of
mutational events is favored [43,44].
The set of indels found was compared with those
already annotated in mitochondrial databases [17,18],
validated through traditional sequencing methods, discri-
minating those found in healthy individuals from those
in diseased patients. About 20% indels observed in our
samples matched with those reported in HmtDB within
healthy samples dataset and nearly 8% were annotated in
patient genomes (Table 2). As expected based on the
NGS technologies power in detecting also low-level het-
eroplasmy [1,45,46], the remaining 80% highlights that
there was a clear-cut prevalence of novel deletions and
insertions, which mostly spanned non-coding regions,
even though coding regions were not completely devoid
of them. Interestingly, a single base insertion at the
Figure 1 1000 Genomes mitochondrial indels distribution. The analysis of 1242 Illumina samples allowed to identify 149 deleted and 66
inserted mitochondrial positions, mostly heteroplasmic. The ratio between the number of homoplasmic and heteroplasmic indels and the
length of mitochondrial loci is reported (normalized indels). The distribution of insertions and deletions within the mitochondrial genome shows
peaks of indels ratio within the D-loop, while a lower number is present within coding regions.
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position 3229 (the 3’end nucleotide of 16s rRNA), single
base deletions in 5747 (OriL, origin of light-strand repli-
cation) and 11032 (MT-ND4), and the extended deletion
in 303-305 (D-Loop) were present only in patients, but
not yet associated to any disease [18]. With respect to the
18 insertions and 15 deletions reported in Mitomap,
some of them are associated to cancer or other diseases,
i.e. a set of D-loop mutations (m.514insCG found in
head/neck tumor, m.568insC(n) found in multiple tumor
types, m.16189insT found in bladder tumor, m.310delT
found in breast tumor), three indels events in the mito-
chondrial gene encoding 12S rRNA, MT-RNR1,
(m.956insC, m.956delC, m.960delC, which are possibly
DEAF-associated) and one deletion in the gene encoding
for tRNA threonine, MT-TT, (m.15940delT found in
multiple myeloma) [17].
Also 3407 single base mismatches were detected within
our samples, involving 3289 unique positions (Additional
File 9), with an average of about 25 mismatches per sam-
ple. They were discriminated between 2330 heteroplas-
mic and 2204 homoplasmic alleles, whose normalized
distributions are shown in Figure 2. Such distributions
are rather homogeneous among mitochondrial loci, with-
out significant dissimilarities between the two types, with
high peaks into non-coding regions. As well as for indels,
we found about 40% mismatches positions spanning
homopolymeric stretches and only 1% within mitochon-
drial variant nucleotide tandem repeats (data not shown).
The majority of single-base homoplasmic variants
(88.48%) was already described in healthy individuals [18]
and 62.75% heteroplasmic ones were annotated in public
databases in a homoplasmic state (Additional File 9). A
large fraction of hetero/homoplasmic mismatches (more
than 50% and 76%, respectively) was also found in
patients. Statistics related to indels and mismatches are
summarized in Table 2.
Heteroplasmy analysis
We detected on average 20 homoplasmic and 8 hetero-
plasmic variants per sample (Additional File 7). Frequency
of variants was estimated for eleven ranges of heteroplas-
mic fractions (HF) (Figure 3). Considering the mean num-
ber of variants for each range of heteroplasmy and the
mean number of alternative alleles in each sample, homo-
plasmic variants represented the largest slice with respect
to the whole set of alleles in an individual. There was a
substantial preponderance of homoplasmies (HF = 1.00),
quasi-homoplasmies (defined as 0.90<HF<0.99) and low-
level heteroplasmies (0.01<HF<0.10), suggested also by a
hierarchical clustering analysis (Additional File 10). We
did not observe correlation between clusters of heteroplas-
mic variants and sample geographical origin.
Pathogenicity analysis of private mutations
After haplogroup assignment, we isolated more than 2500
variants not defining the individual haplogroup, then func-
tionally annotated. Predictions of pathogenicity were car-
ried out on the subset of 543 non-synonymous variant
positions using MutPred [20], Polyphen-2 [21] and
SNPs&GO [22] tools with the aim of identifying poten-
tially damaging alleles and their spread within the 19
populations (Additional File 11 and Additional File 12).
All the 543 missense mismatches were classified according
to the ranges of heteroplasmy, so that 339 were homoplas-
mic and 309 heteroplasmic. Above all, MT-ND5 appeared
to harbor the highest frequency of non-synonymous
changes. Occurrence of variants in the reconstructed
mitochondrial genomes was not exclusive for a particular
world area, but generally a variable number of samples
belonging to different populations shared the same homo-
plasmic and quasi-homoplasmic/highly heteroplasmic
variants, while low-level heteroplasmies were detected
only in single individuals and may hence be likely consid-
ered personal mutations. For example, the m.13105A>G
event was shared by 106 samples belonging to 14 popula-
tions, with the lowest HF equal to 0.87 (Additional
File 11). We focused only on 289 variant sites (148 found
in a homoplasmic state, 183 as heteroplasmic) predicted as
probably pathogenic by at least one of the above men-
tioned software (Additional File 12) and interestingly they
all showed very low variability (mean value = 0.02 for
homoplasmic mutations, 0.03 for the heteroplasmic ones).
Among potentially damaging events, the lowest HF value
was 0.25 (Additional File 11). The most shared variants
within this subset were all in a homoplasmic/highly het-
eroplasmic state. Only 14 non-shared mismatches were
predicted as damaging mutations by the three software,
and among them the m.3946G>A was also annotated in
Mitomap as associated to MELAS (Mitochondrial Ence-
phalomyopathy, Lactic Acidosis and Stroke-like episodes).













Indels 6.05 15.38 0.00 98.60 21.23 7.91
Mismatches 64.69 88.48 76.36 68.39 62.75 53.65
Statistics about homoplasmic and heteroplasmic mitochondrial events are here reported. Events are discriminated between indels and mismatches. The
percentages of homoplasmic and heteroplasmic observed variants annotated in healthy and patients genomes stored in HmtDB [18] are reported. A fraction of
variant sites was found as homoplasmic in any samples and heteroplasmic in others.
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Figure 2 1000 Genomes mitochondrial mismatches distribution. The ratio between the number of mismatches and the length of
mitochondrial loci (normalized mismatches) is reported. Variant distributions are rather homogeneous among mitochondrial loci, without
significant dissimilarities between the two types, with high peaks into non-coding regions.
Figure 3 Enrichment of heteroplasmic fractions within the dataset. Variants frequency was estimated for eleven ranges of heteroplasmic
fractions (HF). The ratio between the mean number of variants for each cluster and the mean number of variants in each sample highlights that
homoplasmic variants represent the largest slice with respect to the whole set of alleles in an individual. With respect to the degree of
heteroplasmy, there is a substantial preponderance of homoplasmic variants (HF = 1.00), quasi-homoplasmies (0.90-0.99) and low-level
heteroplasmies (0.01-0.10).
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They all presented a low variability value (<0.20) and a HF
ranging from 0.29 to 1.00.
The complete list of mitochondrial unique variants
identified is reported in Additional File 2.
Analysis of LCLs and blood samples
As previously observed for nuclear variants [23-25], we
hypothesized that lymphoblastoid cell lines (LCLs) might
have a higher rate of mitochondrial mutations than
blood. Similarly to what already performed for nuclear
variants [23-25], we attempted to identify relevant quali-
tative and quantitative gaps between variants found in
120 out of our 1242 samples, among which 60 were sup-
posed to be derived from blood and 60 from LCLs
(Methods). Samples were not related in families, except
for one CEU trio (NA12878, NA12891, NA12892), and
were representative of 18/19 populations. We first con-
sidered variants occurrence within the two datasets and
their localization in the mitochondrial genome, discrimi-
nating heteroplasmic and homoplasmic sites (Figure 4).
Frequencies were hence normalized to the length of
mitochondrial loci, in order to eliminate biases related to
length. The distribution of variants along mitochondrial
loci showed that generally heteroplasmic and homoplas-
mic mutations occurred at the same loci, which was veri-
fied in both datasets. A statistical relevant difference
between mitochondrial loci distributions of variants
within the two types of samples was found for
heteroplasmic (p < 0.01), but not for homoplasmic var-
iants (Figure 4). The total number of variants was esti-
mated within the two subsets, discriminating also
between indels and mismatches and considering their
heteroplasmy status (see Additional File 7). Minimal sta-
tistically relevant differences were detected between
LCLs and blood derived DNA especially in relation to
indels (p < 0.05).
Variant sites observed in the two different DNA
sources were associated with variability values esti-
mated on nearly 10,000 complete mitochondrial gen-
ome sequences [33] (Figure 5). The trend was similar
for blood and LCL samples: almost all of the variant
positions displayed a very low variability (<0.20)
(Table 3). Positions showing high variability, i.e. those
which were common in the sequenced genomes avail-
able at HmtDB [18], were few and represented the
25% of total shared variants between the 2 datasets,
while the majority of non-shared variants (about 98%)
displayed low variability. Among low variability sites
(<0.20), we found only a minimal numerical difference
in low-level heteroplasmy variants (HF<0.10) enriched
in LCLs, albeit not supported by statistical significance
(Table 3).
In fact, upon analyzing LCLs/blood heteroplasmy
levels (Table 4), we confirmed a LCLs trend to accumu-
late low-level heteroplasmic variants (69 vs 24 in blood
samples), although a comparable average number of
Figure 4 Distribution of homoplasmic and heteroplasmic variants in LCL and blood subsets. Frequencies of homoplasmic and
heteroplasmic variants were normalized to the length of mitochondrial loci, in order to eliminate length biases. Variants distribution across
mitochondrial loci shows that generally heteroplasmic and homoplasmic mutations occur in the same loci, and this is verified in both datasets.
A statistical relevant difference between the distributions of variants within the two datasets was found for heteroplasmic (p < 0.01), but not for
homoplasmic variants.
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heteroplasmic variants per sample was reported for both
LCL and blood samples (7.42 for LCLs, 7.33 for blood
samples). About 25% variants were shared by both sub-
sets and in 80% cases they were homoplasmic.
Discussion
In this paper we report the results obtained by capturing
human mtDNA sequences starting from 1000 Genomes
Whole Exome Sequencing (WES) data specifically
Figure 5 Variability profile of blood and LCL genomes. Variability values estimated on nearly 10,000 mitochondrial nucleotide multi-aligned
sequences, available in HmtDB web site [33] are reported versus the variant positions observed in both blood and LCL samples. The trend is
similar for both datasets: almost all of the variant positions display a very low variability (<0.20). Positions showing high variability, i.e. those
which were common in the genomes within HmtDB, were few and represented the 25% of total shared variants between the two datasets,
while the majority of non-shared variants (about 98%) displayed low variability.
Table 3 Number of variants within LCL and blood subsets, sorted by heteroplasmic fraction and variability score.
Variability Sample HF<0.10 0.11<HF<0.75 0.76<HF<0.99 HF = 1 F-test
≤0.20 LCL 66 120 214 783 0.90
≤0.20 blood 22 119 260 820 0.90
>0.20 LCL 3 6 74 489 0.39
>0.20 blood 2 8 49 542 0.39
The highest number of positions shows low variability (≤0.20), and although no statistically significant difference was observed between the LCLs/blood overall
distributions of variants, an enrichment in low-level heteroplasmies was detected in LCLs low-variability variants.
Table 4 Number of heteroplasmic and homoplasmic variants within blood and LCL samples, sorted by heteroplasmic
fraction
Heteroplasmic Fraction N. of Variant Positions in Blood Samples N. of Variant Positions in LCL Samples











A clear enrichment in very low-level heteroplasmic variant positions within the whole LCL dataset (69 vs 24 in blood samples) may be observed.
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targeted to nuclear genes. WES has been commonly
used with clinical aims since its first application [47],
although this technology has been also implemented in
evolutionary comparison of genomes [48]. Even though
the most recent WES protocols include the use of speci-
fic baits targeted to the whole mitochondrial genome as
well as the MitoCarta set of nuclear genes [49], the
probe sets used in the majority of previously published
WES studies excluded such baits, hence mtDNA
sequences have been considered by-products and
thereby neglected.
For the first time, we here recovered the overlooked
mitochondrial information and reconstructed a large
number of human mitochondrial sequences from off-
target exome data, thanks to the availability of popula-
tion-scale sequence datasets offered by the 1000
Genomes Project [19]. This was possible through the
application of a bioinformatics pipeline aimed at assem-
bling mitochondrial genomes from exome data and then
at annotating insertions, deletions and mismatches,
accompanied by their heteroplasmy fraction, a series of
tasks that were not feasible so far and that are necessary
when dealing with mtDNA data. Overall we managed to
extract 1242 assembled mtDNA, testing the validity of
the protocol on the basis of coverage and quality data of
the mitochondrial genomes that were generated. Further
evidences of the robustness of our method were provided
by the accurate haplogroup assignment, which reflected
individual ethnicity, and by the comparison with the set
of variants within 28 samples selected from the mtDNA
VCF of low-coverage whole genome sequencing data [40]
generated by the Consortium. It has to be underlined
that a fraction of mitochondrial variants (6.47%) anno-
tated in the low coverage report was not identified by our
protocol. This discrepancy may be likely due to variant
artefacts as a consequence of WES probes overlapping
NumtS, which were not filtered out in the 1000 Genomes
project. On the other hand Whole Genome Sequencing
protocols ensure the availability of probes mapping on
the entire mitochondrial genome, therefore some missing
variants derived from the exomes analyzed are linked to
an incomplete covering of any mitochondrial genomes.
Another possible source of discrepancy may be repre-
sented by sequencing errors ruled out by our protocol as
associated to quality scores lower than the minimum
threshold required for variant calling. The analysis of the
reconstructed mitochondrial genomes highlighted a
widespread distribution of polymorphisms in healthy
samples. Noteworthy, a parallelism may be observed
between the enrichment in damaging and probably
damaging rare variants within nuclear low frequency
alleles of the 1000 Genomes Low Coverage [50] and
Exon Pilot Projects [51], and the numerous group of
mitochondrial pathogenic predicted alleles [20-22] and
mutations with a confirmed disease association [17,18],
detected in our dataset.
In fact, Exon Pilot rare variants [51] observed among
continents highlighted a reduction in the degree of allele
sharing, as well as a very low variability was associated
to homoplasmic/heteroplasmic mitochondrial variants
we predicted as damaging, that were mainly observed in
sparse unrelated individuals. Although low variability
may be affected by a bias in the world population sam-
pling, this finding may suggest that, similarly to the
nucleus, negative selection is acting on these mitochon-
drial sites.
Furthermore, similarly to the results on nuclear DNA
reported by Xue et al. [50], a possible explanation of the
presence of pathogenic mitochondrial variants in healthy
samples in a heteroplasmic condition below the specific
threshold for the onset of the disease [8], at least at
the time of recruitment, may be linked to the age of dis-
ease onset or to an incomplete penetrance due to the
absence in the subject of other factors contributing to the
disease; a further explanation may be linked to the pre-
sence of erroneous annotations of disease-associated var-
iants in databases. Indeed only a few variants are currently
annotated as unequivocally disease-causative, i.e. mainly
Leber’s Hereditary Optic Neuropathy (LHON) and Mito-
chondrial Encephalomyopathy, Lactic Acidosis and
Stroke-like episodes (MELAS) mutations [17], while there
is a high degree of uncertainty about the correct disease
association for most of the mitochondrial mutations
reported in literature especially since most of the time
functional studies are lacking. Moreover, no information
about the level of heteroplasmy is reported in mitochon-
drial databases and this is becoming an urgent need, con-
sidering the relationship between heteroplasmy threshold
and clinical manifestation of the disease [8,11] and the
ever increasing power of NGS technology in detecting also
minor alleles in heterogeneous pools of variants
[1,16,45,46]. As recently shown and in line with our find-
ings, a ‘universal heteroplasmy’ of low-level heteroplasmic
variants is present in healthy humans [16], which may not
be disregarded. In this population-scale scenario of variety,
a common event recorded within our dataset is length het-
eroplasmy, that is the coexistence of different lengths of
the same homopolymeric stretch within the same indivi-
dual, mainly occurring within mtDNA control regions and
present at a lower frequency in the coding regions.
Although coding regions are highly populated with homo-
polymeric stretches, the lower occurence of length hetero-
plasmic variants may be due to a negative selection
process acting to avoid function disruption.
As general concerns were expressed about the use of
LCLs-derived DNA for sequencing studies [52], we
further sought differences in LCL versus blood sample
subsets. To the best of our knowledge, no previous study
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showed reports on LCLs and blood mtDNA comparison.
Although in our analyses we lacked paired samples of
blood and LCLs from the same subject, we disposed of
numerous groups of blood and LCL samples from several
unrelated individuals (except for one trio), however suffi-
cient to identify qualitative and quantitative gaps between
the two, considering that EBV transformation may result
in low-level generation of de novo mutations [23-25].
Several works on whole exome/genome sequencing of
LCLs/blood were all in agreement that the great majority
of variants found in paired samples is shared (99% at
least) [23-25], except for a minimal percentage of de novo
variants, also found in low-passages LCLs [24]. A com-
parable result was observed in our mitochondrial blood/
LCL samples: the average number of heteroplasmic var-
iants per type of sample was the same (about 7), even
though we solely observed a difference in the numerical
distribution of heteroplasmic variants along mitochon-
drial loci (Figure 4). However 80% variants shared by
both datasets (25% of all the detected variants) were
homoplasmic and the only numerical, albeit not statisti-
cally significant discrepancy was recorded for very low-
level heteroplasmic alleles (<10%), mostly enriched in
LCLs. Moreover, low variability sites abound among non-
shared variants, which belong to the low-level hetero-
plasmy range of variants observed also in blood samples,
likely a more reliable DNA source than LCLs. This find-
ing is consistent with the general observation among all
19 human populations screened in this study of a specific
enrichment in very low-levels heteroplasmies and, in a
mirrored fashion, quasi-homoplasmies (see Figure 3 and
Additional File 10). As indeed demonstrated for both
pathogenic predicted and LCL/blood variants analyzed,
the majority of low-levels heteroplasmies are unshared
between individuals and also associated with very low
variability, thus more likely represent a bulk of private
variants carried by each individual, as previously sug-
gested [16]. Moreover, in this fashion, our analysis sug-
gests reliability of 1000 Genomes LCL samples and more
generally of early passage EBV-transformed lymphocytes
for mitochondrial genotyping, although validation with
specific molecular methods for the detection of low
heteroplasmies [53] and mtDNA targeted resequencing
of blood-LCL paired-samples would be recommended.
An interesting finding in our analyses concerned the
detection of shared potentially pathogenic variants.
These results raise several questions on the definition of
pathogenicity for an mtDNA change, a debate that has
recently sparked within the mtDNA community and
that calls for an in-depth thinking. The pathogenicity
parameters assigned to nuclear variants may not apply
sic to mitochondrial ones, in the same fashion as the
concept of polymorphism. Because of the peculiarities of
mitochondrial polyplasmic genetics, the assignment of
pathogenicity ought to take into account the degree of
heteroplasmy, the haplogroup/haplotype context, and even
environmental factors. For instance, a report describes a
common European variant as predisposing to breast can-
cer in African women, which puts a red alert sign on the
need for clarification in this field [54]. Overall, unless sup-
ported by clear-cut functional studies, mtDNA variants
ought not to be considered pathogenic independently on
the abovementioned factors. These considerations also
draw attention on the true existence of a variant. On one
side, it appears striking that we detected a large number of
previously unreported variants, in a database that contains
nearly 10,000 mitochondrial genomes, a large number of
which at very low heteroplasmy levels. This may not
appear surprising since they may be detected exclusively if
highly sensitive methods are applied, such as deep sequen-
cing. Nonetheless, one ought to consider that the increas-
ing sensitivity of sequencing strategies allows the detection
of low heteroplasmy degrees, but a limit is reached across
which it becomes impossible to distinguish between a true
low heteroplasmy and errors, intuitively. From a biological
standpoint, extremely low heteroplasmic variants, being
these potentially pathogenic or not, may rarely have a phy-
sio-pathological meaning (unless they may become ampli-
fied during transmission to offspring). We may not
assume that all variants here detected in blood-extracted
samples were germ-line, as blood is indeed a somatic
tissue. With this in mind, one has to ask whether the
occurrence of very low variants in a somatic tissue may be
more than a completely random transient event, and
therefore whether annotation of such variants is a neces-
sary task. Theoretically, every position in the mtDNA may
vary in a single copy and be detected before evolution or
random drift act to amplify it or to revert it, therefore a
consensus must be reached for annotation of very low
heteroplasmic data.
Overall, we believe that the accurate annotation of the
heteroplasmy degree of mitochondrial variants, which is
of paramount importance especially in clinical studies,
should be better implemented in up-to-date mitochon-
drial databases. Indeed, the combined use of several
information, such as the health status of individuals, the
biological source of DNA, the heteroplasmic status of
variants, the prediction of pathogenicity and the hap-
logroup assignment should be a valuable tool for the
definition of general criteria of prioritization of mito-
chondrial disease-associated variants.
Conclusions
To the best of our knowledge, this is likely the most
extended population-scale mitochondrial genotyping in
humans, enriched with the estimation of heteroplasmies.
We used a pipeline to extract and characterize mito-
chondrial genomes from 1000 Genomes Whole Exome
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Sequencing data, previously disregarded in these indivi-
duals. The application of our protocol offers also the
relevant opportunity to further use this information,
coupled with the nuclear genotype, for nuclear/mito-
chondrial coevolution studies both in health and disease.
Additional material
Additional File 1: Samples annotation integrated with haplogroup
assignment, mitochondrial coverage and per base depth.
Information about ethnicity, gender, mitochondrial genome coverage
and the capture technology used for the 1242 samples, is available at
the 1000 Genomes web site [26]. Haplogroup for each sample is also
reported, predicted through the mt-classifier tool in HmtDB [18]. The
1000 Genomes Phase 1 data collection included 827 out of 1242
samples, while the remaining 415 are additional individuals, listed within
the 2012-05-22 exome alignment index [27], which comprised all the
exome samples aligned by the Consortium. Twenty-eight low coverage
samples were used as controls to validate mitochondrial variants
detected in exome samples.
Additional File 2: List of mitochondrial variants identified. All the
mitochondrial variant positions and related reference and variant alleles
identified within 1242 exome samples are listed in a BED format file,
reporting 0-based start and 1-based end coordinates.
Additional File 3: Depth of coverage of 723 Agilent samples and
515 NimbleGen samples. For each analyzed sample the median depth
of coverage was estimated within each mitochondrial locus, starting
from per base depth values. A better efficiency in mitochondrial reads
extraction was obtained with the Agilent (A) kit of enrichment, as
suggested by comparing the highest mitochondrial depth values
obtained through the Agilent (274.57X) protocol with that reached by
the NimbleGen (B, 55.67X) samples within the same locus, MT-ND6. MT-
TS1 (64.99X) and MT-TN (26.44X) show the lowest depth through Agilent
and NimbleGen capturing, respectively.
Additional File 4: Quality score of 723 Agilent samples and 515
NimbleGen samples. Median quality score was estimated for each
analyzed sample within each mitochondrial locus starting from quality
score of single positions. Agilent (A) mitochondrial reads show slightly
higher QS than NimbleGen (B): both capture technologies recorded the
maximum score within the same locus, MT-TS2 (Agilent 35.82,
NimbleGen 33.13), while the lowest value is within MT-TR (34.30 with
Agilent, 31.47 with NimbleGen). Moreover Agilent QSs seem to have a
more uniform trend than Nimblegen ones.
Additional File 5: Variants detected by whole genome low coverage
and exome sequencing. The whole set of variant sites identified within
28 analyzed exome samples is here compared with that detected within
the same samples obtained through whole genome low coverage
sequencing by the 1000 Genomes Consortium. Each mutation identified
by the two methods is reported, integrated with information about
homoplasmic/heteroplasmic state within the samples. For 1282/1376
variants, heteroplasmic fractions (HF) estimated by our pipeline are
shown, while depth of coverage within exome samples is reported for
each position.
Additional File 6: Indels identified in assembled mitochondrial
genomes. The total number of heteroplasmic and homoplasmic indel
events (149 deletions and 66 insertions) recorded within the analyzed
dataset is here reported. The frequency of each event was estimated
considering the dataset size (1242 samples). Fifty-three percent samples
display an insertion in the same position, namely the m.310insC(n). Over
half of the total events was not carried by more than one sample. The
previously reported annotation of these events in healthy and patients
was made after consulting HmtDB [18] and Mitomap [17] databases.
Additional File 7: Spectrum of mitochondrial mutations within the
1242 analyzed samples. The number of mitochondrial variants
identified in each sample is here reported. A sorting was made on the
heteroplasmic/homoplasmic state and mutation type. Average values
and statistical tests results are reported at the end of the table. The
mean number of variants was estimated within the whole dataset and
also within the two subsets (blood and LCLs). P-value of significance
referred to each class of variants (insertions, deletions, mismatches)
compared between blood and LCLs. Minimal differences were detected
between the two types of samples, especially in relation to indels (p <
0.05). The differences between mean values of heteroplasmic variants per
sample in LCLs (7.42) and in blood (7.33) were not statistically significant.
Additional File 8: Indels found within homopolymeric stretches.
Almost all of the identified indels (72.09%) occur within homopolymeric
stretches, defined as regions with the same nucleotide in at least two
adjacent positions. The figure shows how indels are distributed on the
basis of homopolymers length. The shortest homopolymers harbor the
highest number of indels, although 5-bases stretches present high levels
of both deletions and insertions too. Low frequency of indel events was
observed within G-stretches.
Additional File 9: Mismatches identified in assembled mitochondrial
genomes. The total number of heteroplasmic (2330) and homoplasmic
(2204) mismatches events recorded within the analyzed dataset is here
reported. The number of samples harboring a specific mismatch in a
heteroplasmic or homoplasmic state is also shown. About 84% samples
display a mismatch in the same position (m.263A>G), explained by the
fact that this event is defined as one of the seven rare rCRS
polymorphisms. Over half of the total events was not harbored by more
than 1 sample. The annotation of these events in healthy subjects and
patients was made using data annotated in HmtDB [18] and Mitomap
[17] databases.
Additional File 10: Hierarchical clustering of heteroplasmic fractions.
A hierarchical clustering based on Euclidean distance was performed to
evidence shared classes of heteroplasmy within individuals with the aim
to identify a possible clusterization of samples belonging to the same
population sharing a similar number of variants referred to the same
heteroplasmic range. There is a substantial preponderance of
homoplasmic variants (1.00), quasi-homoplasmies (0.90-0.99) and low-
level heteroplasmies (0.01-0.10). The white area corresponds to samples
carrying at most 1 variant, due to a poor mitochondrial genome
coverage. The crowding of “leaves” in the lowest levels of the tree
highlights lack of correlation among heteroplasmic clusters and the
sample geographical origin.
Additional File 11: Non-synonymous changes within analyzed
samples. After the haplogroup assignment, 543 non-synonymous variant
positions were detected, which do not define the individual haplogroup.
Among them, 339 were found as homoplasmic and 309 as
heteroplasmic. Heteroplasmic fraction (HF) of missense mismatches and
samples ethnicity are reported.
Additional File 12: Functional annotation of non-synonymous
mismatches in 943 samples. Predictions of pathogenicity were carried
out on 543 non-synonymous mismatches previously filtered, using
MutPred [20], Polyphen-2 [21] and SNPs&GO [22] tools. Localization of
mismatches, the homoplasmic/heteroplasmic state, the corresponding
aminoacid change and nucleotide variability values estimated on nearly
10,000 mitochondrial nucleotide multi-aligned sequences, downloaded
from [33], are reported. Above all, MT-ND5 appeared to harbor the
highest frequency of non-synonymous changes. All the variants
predicted as probably pathogenic by at least one of the
abovementioned software (148 homoplasmic and 183 heteroplasmic)
show very low variability (mean value = 0.02 for homoplasmic mutations,
0.03 for the heteroplasmic ones). Only 14 non-shared mismatches were
predicted as damaging mutations by the three software, and among
them the m.3946G>A was also annotated in Mitomap [17] as associated
to MELAS.
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HF: Heteroplasmic Fraction; MELAS: Mitochondrial Encephalomyopathy,
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